A new clinical trial involving insulin glargine was registered, with an update dated July 22, 2026. The trial, titled "CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial," is listed under identifier NCT07652528.
The study is currently listed as not yet recruiting. Its phase is designated as not applicable. The trial aims to compare a CGM-guided patch pump approach against basal-bolus injection therapy, which includes insulin glargine, in managing steroid-induced hyperglycemia among patients being treated for sudden sensorineural hearing loss.
No results have been posted for this trial at this time. The current record reflects only the trial's registration status and design as of the stated date. Readers should not interpret this update as evidence of safety or effectiveness for either treatment approach, since no outcome data have been reported.
Further details on the trial's design, eligibility, and status can be found through the official trial listing. As the study has not yet begun recruiting participants, timelines for enrollment and results remain undetermined. For more background on insulin glargine, see the compound overview.